WCD Pacing Analgesia via Electrolyte Drug Delivery
Solution Overview
Problem
Current wearable cardioverter defibrillator (WCD) systems are unable to effectively treat asystolic arrest, as conscious patients cannot tolerate the pain of transthoracic pacing, leading to potential removal of the WCD and loss of therapy.
Innovation Solution
The WCD system is enhanced with a transthoracic pacing capability and the ability to deliver a pain-reducing drug, such as lidocaine, directly to the patient's skin through the therapy electrode electrolyte, either before or during pacing therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transthoracic pacing is provided to treat asystolic arrest, then the patient can receive life-saving therapy, but the conscious patient experiences pain and may remove the WCD
Solution Approach 1:
The patent introduces an intermediary substance (anesthetic agent or electrolyte gel) between the pacing electrode and the patient's skin. This intermediary reduces the pain of transthoracic pacing by numbing the skin or improving current distribution, allowing conscious patients to tolerate the life-saving therapy without removing the WCD.
Solution Approach 2:
The system applies the anesthetic agent or electrolyte gel to the patient's skin before delivering transthoracic pacing therapy. This preliminary action ensures that the skin is prepared and numb before the painful pacing shocks are administered, enabling the patient to remain conscious and keep the WCD in place throughout treatment.
2Ease of operation
If a pain-reducing drug is delivered through the therapy electrode electrolyte, then patient tolerance of pacing therapy improves, but the system complexity increases
Solution Approach 1:
The patent merges the pain-reducing function with the existing therapy electrode electrolyte system. By incorporating anesthetic agents or enhancing electrolyte gel properties within the existing electrode structure, the system achieves pain reduction without adding separate complex drug delivery mechanisms, thus improving patient tolerance while minimizing system complexity.
Solution Approach 2:
The therapy electrode electrolyte serves multiple functions: it maintains electrical conductivity for pacing therapy and simultaneously delivers pain-reducing medication. This multi-functionality allows the same component to address both therapeutic and comfort needs, reducing overall system complexity while improving patient tolerance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This solution allows conscious patients to tolerate pacing therapy, reducing the likelihood of WCD removal and ensuring continued therapy, thereby improving patient outcomes during asystolic events.
Implementation Method 1
a pain-reducing drug is included in the therapy electrode electrolyte
Data Source
AI summary
An external defibrillator system such as a WCD is also capable of providing transthoracic pacing and drug delivery (e.g., pain-reducing drugs and/or a sedatives) to a patient. The drug(s) may be included in the therapy electrode electrolyte and dispensed for defibrillation, cardioversion and/or pacing therapy. Alternatively, the drug(s) may be stored in a separate reservoir and dispensed during pacing therapy. The drug(s) may be dispensed to a patient after a successful defibrillation therapy. The pacing therapy may be delivered a set time-period after the drug(s) were dispensed. A relatively small electric current may be delivered to the area of the patient on which the drug(s) were dispensed to facilitate drug absorption.